Patents by Inventor Francois Conquet

Francois Conquet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200171042
    Abstract: The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with levodopa.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 4, 2020
    Inventors: Delphine Charvin, François Conquet
  • Publication number: 20200024285
    Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 23, 2020
    Inventors: Delphine Charvin, Baptiste Manteau, Vincent Pomel, François Conquet
  • Patent number: 10532057
    Abstract: The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with ievodopa.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 14, 2020
    Assignee: Prexton Therapeutics SA
    Inventors: Delphine Charvin, François Conquet
  • Patent number: 10442818
    Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: October 15, 2019
    Assignee: Prexton Therapeutics SA
    Inventors: Delphine Charvin, Baptiste Manteau, Vincent Pomel, François Conquet
  • Publication number: 20180291034
    Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
    Type: Application
    Filed: June 5, 2018
    Publication date: October 11, 2018
    Applicant: Prexton Therapeutics SA
    Inventors: Delphine CHARVIN, Baptiste MANTEAU, Vincent POMEL, François CONQUET
  • Publication number: 20180271874
    Abstract: The present invention provides a chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to the neuroexcitatory amino acid glutamate and presents an advantageously high brain exposure upon oral administration, for the treatment or prevention of levodopa-induced dyskinesia. The present invention also provides an improved therapy of Parkinson's disease, using the chromone oxime derivative of formula (I) in combination with ievodopa.
    Type: Application
    Filed: August 26, 2016
    Publication date: September 27, 2018
    Inventors: Delphine CHARVIN, François CONQUET
  • Patent number: 10017521
    Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: July 10, 2018
    Assignee: Prexton Therapeutics SA
    Inventors: Delphine Charvin, Baptiste Manteau, Vincent Pomel, François Conquet
  • Publication number: 20170253613
    Abstract: The present invention provides a novel chromone oxime derivative of formula (I), which is a modulator of nervous system receptors sensitive to glutamate and, furthermore, presents an advantageously high brain penetration upon oral administration. The invention also relates to a pharmaceutical composition containing this compound, and to its use for the treatment or prevention of conditions associated with altered glutamatergic signalling and/or functions, or conditions which can be affected by alteration of glutamate level or signalling, particularly acute and chronic neurological and/or psychiatric disorders.
    Type: Application
    Filed: August 27, 2015
    Publication date: September 7, 2017
    Inventors: Delphine CHARVIN, Baptiste MANTEAU, Vincent POMEL, François CONQUET
  • Publication number: 20030195139
    Abstract: An antagonist of the metabotropic glutamate receptor 5 (mGluR5) is useful in tolerance or dependence therapy. Such an antagonist can therefore be used in the treatment of substance tolerance or dependence, bulimia nervosa, anorexia nervosa, gambling dependence, sex dependence or obsessive compulsive disorders.
    Type: Application
    Filed: April 14, 2003
    Publication date: October 16, 2003
    Inventors: Mauro Corsi, Francois Conquet